129 related articles for article (PubMed ID: 37877739)
1. Design, synthesis, and in-silico study of novel triarylethylene analogs with dual anti-estrogenic and serotonergic activity.
Mostafa T; Albeir M; Wober J; Abadi A; Salama I; Ahmed NS
Drug Dev Res; 2024 Feb; 85(1):e22127. PubMed ID: 37877739
[TBL] [Abstract][Full Text] [Related]
2. Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs.
Elnakib HE; Ramsis MM; Albably NO; Vector MA; Weigand JJ; Schwedtmann K; Wober J; Zierau O; Vollmer G; Abadi AH; Ahmed NS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830456
[TBL] [Abstract][Full Text] [Related]
3. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Rasmussen LM; Zaveri NT; Stenvang J; Peters RH; Lykkesfeldt AE
Breast Cancer Res Treat; 2007 Dec; 106(2):191-203. PubMed ID: 17268816
[TBL] [Abstract][Full Text] [Related]
4. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.
Ahmed NS; Elghazawy NH; ElHady AK; Engel M; Hartmann RW; Abadi AH
Eur J Med Chem; 2016 Apr; 112():171-179. PubMed ID: 26896706
[TBL] [Abstract][Full Text] [Related]
6. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
[TBL] [Abstract][Full Text] [Related]
7. Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation.
Sreeja S; Santhosh Kumar TR; Lakshmi BS; Sreeja S
J Nutr Biochem; 2012 Jul; 23(7):725-32. PubMed ID: 21839626
[TBL] [Abstract][Full Text] [Related]
8. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
9. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
11. The modulatory role of low concentrations of bisphenol A on tamoxifen-induced proliferation and apoptosis in breast cancer cells.
Huang B; Luo N; Wu X; Xu Z; Wang X; Pan X
Environ Sci Pollut Res Int; 2019 Jan; 26(3):2353-2362. PubMed ID: 30467747
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
[TBL] [Abstract][Full Text] [Related]
13. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
14. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
16. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.
Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ
Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
Lv W; Liu J; Skaar TC; O'Neill E; Yu G; Flockhart DA; Cushman M
J Med Chem; 2016 Jan; 59(1):157-70. PubMed ID: 26704594
[TBL] [Abstract][Full Text] [Related]
20. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
Power KA; Thompson LU
Breast Cancer Res Treat; 2003 Oct; 81(3):209-21. PubMed ID: 14620916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]